Akebia Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-04-14$1.56 RISE2026-05-19$0.90 PEAK2026-05-28$1.05 44d | -42.6% 35d | Missed | Missed | — | — | +17.3% 9d | Missed |
DROP2025-10-27$3.17 RISE2026-02-20$1.18 PEAK2026-04-14$1.56 169d | -62.8% 116d | Missed | Missed | — | — | +32.2% 53d | Missed |
DROP2025-10-27$3.17 RISE2026-02-19$1.18 PEAK2026-04-14$1.56 169d | -62.8% 115d | Missed | Missed | — | — | +32.2% 54d | Missed |
DROP2025-10-27$3.17 RISE2026-02-18$1.18 PEAK2026-04-14$1.56 169d | -62.8% 114d | Missed | Missed | — | — | +32.2% 55d | Missed |
DROP2025-08-06$3.79 RISE2025-12-02$1.47 PEAK2025-12-24$1.70 140d | -61.2% 118d | Missed | Missed | — | — | +15.6% 22d | Missed |
DROP2025-03-19$2.84 RISE2025-04-10$1.55 PEAK2025-07-09$3.99 112d | -45.4% 22d | Missed | Missed | — | — | +157.4% 90d | Missed |
DROP2024-12-02$2.13 RISE2025-01-10$1.75 PEAK2025-03-19$2.84 107d | -17.8% 39d | Missed | Missed | — | — | +62.3% 68d | Missed |
DROP2024-08-30$1.55 RISE2024-10-10$1.28 PEAK2024-12-02$2.13 94d | -17.4% 41d | Missed | Missed | — | — | +66.4% 53d | Missed |
DROP2024-08-30$1.55 RISE2024-10-09$1.28 PEAK2024-12-02$2.13 94d | -17.4% 40d | Missed | Missed | — | — | +66.4% 54d | Missed |
DROP2024-08-30$1.55 RISE2024-10-01$1.28 PEAK2024-12-02$2.13 94d | -17.4% 32d | Missed | Missed | — | — | +66.4% 62d | Missed |
DROP2024-04-02$1.58 RISE2024-08-09$1.11 PEAK2024-11-04$1.85 216d | -29.7% 129d | Missed | Missed | — | — | +66.7% 87d | Missed |
DROP2024-03-27$2.24 RISE2024-06-25$0.86 PEAK2024-08-26$1.55 152d | -61.7% 90d | Missed | Missed | — | — | +80.9% 62d | Missed |
DROP2024-01-29$1.79 RISE2024-02-23$1.35 PEAK2024-03-27$2.24 58d | -24.6% 25d | Missed | Missed | — | — | +65.9% 33d | Missed |
DROP2023-08-01$1.84 RISE2023-10-25$0.80 PEAK2024-01-10$1.58 162d | -56.5% 85d | Missed | Missed | — | — | +97.5% 77d | Missed |
DROP2023-05-24$1.43 RISE2023-07-06$0.87 PEAK2023-08-01$1.84 69d | -39.3% 43d | Missed | Missed | — | — | +112.0% 26d | Missed |
1–15 / 27 1 / 2 | |||||||
No scored news yet for a sentiment trend.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY. A live webcast of the presentation can be accessed through th
I initiate Q32 Bio (QTTB) at 'Buy' due to advancing bempikibart for Alopecia Areata and strong upcoming catalysts.
The United States market has shown robust performance, with a 1.2% increase over the last week and a substantial 29% rise over the past year, alongside an optimistic forecast for earnings growth of 17% annually. In light of these conditions, investors might find opportunity in stocks that balance affordability with potential growth, particularly those often labeled as penny stocks. While the term may seem outdated, these smaller or newer companies can offer intriguing prospects when backed by...
The United States market has shown robust performance, with a 1.2% increase over the last week and a substantial 29% rise over the past year, alongside an optimistic forecast for earnings growth of 17% annually. In light of these conditions, investors might find opportunity in stocks that balance affordability with potential growth, particularly those often labeled as penny stocks. While the term may seem outdated, these smaller or newer companies can offer intriguing prospects when backed by...
One of the biggest stories of last week was how Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares plunged 23% in the...
One of the biggest stories of last week was how Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares plunged 23% in the...
Second, continue to build the clinical evidence to make Vafseo standard of care for patients on dialysis; and third, execute on our impressive kidney disease-focused clinical development pipeline. Earlier in Q1, at the Annual Dialysis Conference, we presented an economic analysis on the cost of hospitalizations for patients treated with Vadadustat versus darbepoetin.
Second, continue to build the clinical evidence to make Vafseo standard of care for patients on dialysis; and third, execute on our impressive kidney disease-focused clinical development pipeline. Earlier in Q1, at the Annual Dialysis Conference, we presented an economic analysis on the cost of hospitalizations for patients treated with Vadadustat versus darbepoetin.
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDTCompany ParticipantsMercedes Carrasco - Senior Director of Investor &...
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to Akebia's First Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised
Akebia Therapeutics (NASDAQ:AKBA) executives highlighted a “strong start” to 2026 on the company’s first-quarter earnings call, pointing to record quarterly net product revenue for its anemia drug Vafseo, expanding use of observed dosing protocols at dialysis organizations, and continued progress ac
Akebia Therapeutics (NASDAQ:AKBA) executives highlighted a “strong start” to 2026 on the company’s first-quarter earnings call, pointing to record quarterly net product revenue for its anemia drug Vafseo, expanding use of observed dosing protocols at dialysis organizations, and continued progress ac
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -125.56% and -5.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -125.56% and -5.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported revenue was USD 53.54 million compared to USD 57.34 million...
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) Akebia to host conferen
CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Akebia Therapeutics Inc. on Thursday reported a first-quarter loss of $9.1 million, after reporting a profit in the same period a year earlier. The...
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 200 percent decrease over earnings of $0.03 per share from the same period last year.
United Therapeutics (UTHR) delivered earnings and revenue surprises of -13.58% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) delivered earnings and revenue surprises of -13.58% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AKBA | -27.14% | -19.05% | -36.65% | -66.34% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -30.11% | -13.33% | -33.20% | -79.03% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 11.61M | $16.14M | 0.00% | Trimmed-15.1% | 2026-03-31 |
| RenTech | quant | 1.83M | $2.55M | 0.00% | Trimmed-49.0% | 2026-03-31 |
| FidelityFMR | fundamental | 1.34M | $1.86M | 0.00% | Added+18.6% | 2026-03-31 |
| TwoSigma | quant | 1.30M | $1.80M | 0.00% | Added+1332.2% | 2026-03-31 |
| Wellington | fundamental | 707.7K | $983.76K | 0.00% | Trimmed-10.0% | 2026-03-31 |
| DEShaw | quant | 16.1K | $22.39K | 0.00% | Added+3.8% | 2026-03-31 |
| TRowePrice | fundamental | 249.2K | $347 | 0.00% | Added+17.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.02 | — | — |
| 2026-05-07 | -0.03 | -0.03 | -7.14% |
| 2026-02-26 | -0.04 | -0.05 | -38.89% |
| 2025-11-10 | — | — | +100.00% |
| 2025-08-07 | -0.02 | — | +100.00% |
| 2025-05-08 | -0.04 | 0.02 | +161.75% |
| 2025-03-13 | -0.07 | -0.10 | -33.33% |
| 2024-11-07 | -0.05 | -0.10 | -100.00% |
| 2024-08-08 | -0.05 | -0.04 | +20.00% |
| 2024-05-09 | -0.09 | -0.08 | +6.33% |
| 2024-03-14 | -0.04 | — | +100.00% |
| 2023-11-08 | -0.08 | -0.08 | +10.53% |
| 2023-08-25 | -0.02 | -0.06 | -141.20% |
| 2023-05-08 | -0.15 | -0.14 | +5.80% |
| 2023-03-09 | -0.16 | -0.03 | +78.49% |
| 2022-11-03 | -0.12 | -0.29 | -138.33% |